In drug screening, a biobank of organoids derived from pancreatic ductal adenocarcinoma enabled the evaluation of 76 therapeutic agents, identifying the PRMT5 inhibitor (EZP015556) as effective in both MTAP-positive and MTAP-negative organoids, emphasizing the importance of personalized approaches in oncology. This evidence concerns the gene MTAP and pancreatic ductal adenocarcinoma.